Suppr超能文献

子宫颈鳞状细胞癌中程序性死亡配体1 [PD-L1] 的表达及错配修复状态

Expression of Programmed Death Ligand 1 [PD-L1] and Mismatch Repair Status in Squamous Cell Carcinomas of Cervix.

作者信息

Anju G, Rao Meenakshi, Elhence Poonam Abhay, Nalwa Aasma, Singh Pratibha, Yadav Garima, Goel Akhil Dhanesh, Thiruvengadam Devisowmiya

机构信息

Department of Pathology & Lab Medicine, All India Institute of Medical Sciences, Jodhpur, Jodhpur, Rajasthan India.

Department of Obstetrics & Gynaecology, All India Institute of Medical Sciences, Jodhpur, Jodhpur, Rajasthan India.

出版信息

J Obstet Gynaecol India. 2024 Aug;74(4):319-325. doi: 10.1007/s13224-023-01837-w. Epub 2024 Jan 20.

Abstract

BACKGROUND AND OBJECTIVES

To assess mismatch repair (MMR) status and programmed death-ligand 1 (PD-L1) expression in squamous cell carcinomas of the cervix and their association with clinicopathologic parameters.

MATERIAL AND METHODS

Expression of PD-L1 and MMR status (MSH2, MSH6, MLH1, and PMS2) was assessed on 50 cases of SCCs of the cervix by immunohistochemistry.

RESULTS

80% of tumor cells and 84% of tumor-infiltrating lymphocytes showed PD-L1 expression. 80% of cases had a combined positive score (CPS) of > 1, whereas 20% had a CPS of < 1. 94% of cases showed pMMR proteins, while 6% showed dMMR. 94% of the SCCs were HPV associated, and 6% were HPV-independent. All HPV-independent SCCs of the cervix showed PD-L1 expression, and all HPV-associated SCCs showed MMR deficiency. Between PD-L1 expression in the tumor and the grade of the tumor, a statistically significant association was noted ( = 0.022). All MMR-deficient SCCs were HPV-independent.

CONCLUSION

This research highlighted the HPV association in cervical SCCs in the Indian population. Most of the cervical SCCs were HPV-associated. Furthermore, most of the HPV-associated SCCs were MMR stable. This study found no significant association between MMR status and PD-L1 expression in cervical SCCs.

摘要

背景与目的

评估子宫颈鳞状细胞癌中的错配修复(MMR)状态和程序性死亡配体1(PD-L1)表达及其与临床病理参数的相关性。

材料与方法

通过免疫组织化学对50例子宫颈鳞状细胞癌病例评估PD-L1表达和MMR状态(MSH2、MSH6、MLH1和PMS2)。

结果

80%的肿瘤细胞和84%的肿瘤浸润淋巴细胞显示PD-L1表达。80%的病例联合阳性评分(CPS)>1,而20%的病例CPS<1。94%的病例显示pMMR蛋白,而6%显示dMMR。94%的鳞状细胞癌与HPV相关,6%与HPV无关。所有子宫颈HPV非依赖性鳞状细胞癌均显示PD-L1表达,所有HPV相关性鳞状细胞癌均显示MMR缺陷。肿瘤中PD-L1表达与肿瘤分级之间存在统计学显著相关性(=0.022)。所有MMR缺陷的鳞状细胞癌均为HPV非依赖性。

结论

本研究突出了印度人群子宫颈鳞状细胞癌中HPV的相关性。大多数子宫颈鳞状细胞癌与HPV相关。此外,大多数HPV相关性鳞状细胞癌MMR稳定。本研究发现子宫颈鳞状细胞癌中MMR状态与PD-L1表达之间无显著相关性。

相似文献

1
Expression of Programmed Death Ligand 1 [PD-L1] and Mismatch Repair Status in Squamous Cell Carcinomas of Cervix.
J Obstet Gynaecol India. 2024 Aug;74(4):319-325. doi: 10.1007/s13224-023-01837-w. Epub 2024 Jan 20.
3
DNA mismatch repair defect and intratumor heterogeneous deficiency differently impact immune responses in diffuse large B-cell lymphoma.
Oncoimmunology. 2024 Aug 5;13(1):2384667. doi: 10.1080/2162402X.2024.2384667. eCollection 2024.
5
Comparison of PD-L1 expression and MMR status between primary and matched metastatic lesions in patients with cervical cancer.
J Cancer Res Clin Oncol. 2023 Oct;149(13):11397-11410. doi: 10.1007/s00432-023-05020-6. Epub 2023 Jun 28.
6
Characterization of mismatch-repair/microsatellite instability-discordant endometrial cancers.
Cancer. 2024 Feb 1;130(3):385-399. doi: 10.1002/cncr.35030. Epub 2023 Sep 26.
9
PD-L1 expression in vulvar cancer: a systematic review and meta-analysis.
Histopathology. 2024 Apr;84(5):742-752. doi: 10.1111/his.15112. Epub 2023 Dec 12.

本文引用的文献

2
PD-L1, PARP1, and MMRs as potential therapeutic biomarkers for neuroendocrine cervical cancer.
Cancer Med. 2021 Jul;10(14):4743-4751. doi: 10.1002/cam4.4034. Epub 2021 Jun 2.
3
Cervical Cancer Immunotherapy: Facts and Hopes.
Clin Cancer Res. 2021 Sep 15;27(18):4953-4973. doi: 10.1158/1078-0432.CCR-20-2833. Epub 2021 Apr 22.
5
PD-L1 expression is associated with tumor infiltrating lymphocytes that predict response to NACT in squamous cell cervical cancer.
Virchows Arch. 2021 Mar;478(3):517-525. doi: 10.1007/s00428-020-02922-5. Epub 2020 Sep 11.
6
PD-L1 Distribution and Perspective for Cancer Immunotherapy-Blockade, Knockdown, or Inhibition.
Front Immunol. 2019 Aug 27;10:2022. doi: 10.3389/fimmu.2019.02022. eCollection 2019.
7
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study.
J Clin Oncol. 2019 Jun 10;37(17):1470-1478. doi: 10.1200/JCO.18.01265. Epub 2019 Apr 3.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验